DIRECTSEQ BIOSCIENCES, INC
DIRECTSEQ BIOSCIENCES
Leading in Sequencing and Genomic Industry
Our Mission
DSI is dedicated to uncovering the truly complete sequences of DNA/RNA, identifying DNA/RNA modifications, understanding their implications, and applying this knowledge for disease diagnosis and treatment, personalized medicine, and identification.
Our Vision
As a leader in sequencing and genomics, we provide a comprehensive and precise approach to decoding the complete range of RNA sequence information. Our patented technologies allow for exhaustive sequencing of all RNA sequences without omissions, and direct sequencing of RNA modifications without bias. These capabilities are essential for advancing RNA research and drug development.
About Us
DirectSeq Biosciences, Inc. (DSI) is revolutionizing the genomic industry with a novel RNA sequencing platform that offers three unprecedented capacities: 1) exhaustive sequencing of every RNA sequence without omission (targeting all RNA molecules), 2) unbiased sequencing of all RNA modifications (targeting all RNA nucleotides, modified or not), and 3) global profiling of RNA and its modifications in human diseases (targeting all RNA and modification changes).
Unlike NGS or nanopore-based methods, DSI has patented next generation mass spectrometry-based RNA sequencing platform technology. It has elevated mass spectrometry to allow for de novo base calling of the four canonical nucleotides (A, C, G, and U) as well as over 170 types of modified nucleotides, providing an unbiased view of all RNA modifications. This capability addresses key challenges in RNA research and is crucial for the development of RNA-based therapeutics (National Academies of Sciences, Engineering, and Medicine, 2024, https://doi.org/10.17226/27165).
DSI's unique sequencing capabilities hold the potential to reveal the complete sequence of RNA molecules for the first time, setting the foundation for the world's first Human Epitranscriptome Project. This initiative aims to draft the first complete sequence of all human RNA molecules and their modifications, poised to be as significant as the Human Genome Project completed in 2003.
Recognized as a breakthrough, this technology is set to assist the FDA in establishing new standards for the safety of RNA-based drugs and propel research into RNA and modification variations associated with age, cancer, and other conditions.
Our sequencing technology has received support from multiple NIH grants and a distinguished client base, including top research universities like the University of Chicago and Cornell Medical School. As we continue to advance, we invite investment and collaboration from those who share our dedication to transforming genomics and improving human health.
Our Technology
Next Generation Mass Spectrometry-Based Sequencing
DSI leads the genomic industry by offering three unprecedented capacities: 1) exhaustive sequencing of every RNA sequence without omission (targeting all RNA molecules), 2) unbiased sequencing of all RNA modifications (targeting all RNA nucleotides, modified or not), and 3) global profiling of RNA and its modifications in human diseases (targeting all RNA and modification changes).
DSI has patented next generation mass spectrometry-based RNA sequencing platform technology. It has elevated mass spectrometry to allow for de novo base calling of the four canonical nucleotides (A, C, G, and U) as well as over 170 types of modified nucleotides, providing an unbiased view of all RNA modifications and their changes in cellular and disease conditions. This technology is set to assist the FDA in establishing new standards for the safety of RNA-based drugs and propel research into RNA and modification variations associated with age, cancer, and other conditions.
Our Team.
"The best way to predict the future is to create it"
Abraham Lincoln
Contact Us
Address
1855 Broadway, EGGC Rm 708
New York, NY 10023
Contact
332-203-2312
Hours
Mon - Fri
9:00 am – 5:00 pm